Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normagut in Irritable Bowel Syndrome
NCT05451433Unknown
- Sponsor
- Faculty of Medicine, Universitas Indonesia
- Start
- Aug 2022
- Primary completion
- Aug 2022
- Modality
- Microbiome Therapeutics
01
Overview
Randomised, double-blind trial of saccharomyces boulardii in irritable bowel syndrome (IBS), sponsored by Faculty of Medicine, Universitas Indonesia. Primary endpoint: Quality of Life at 29 days. Status: unknown.
02
Drugs
saccharomyces boulardii
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05451433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451433.